Alex Sapir - Net Worth and Insider Trading
Alex Sapir Net Worth
The estimated net worth of Alex Sapir is at least $2 Million dollars as of 2024-11-05. Alex Sapir is the President & CEO of Dova Pharmaceuticals Inc and owns about 68,609 shares of Dova Pharmaceuticals Inc (DOVA) stock worth over $2 Million. Alex Sapir is also the See Remarks of Fulcrum Therapeutics Inc and owns about 43,360 shares of Fulcrum Therapeutics Inc (FULC) stock worth over $142,438. Details can be seen in Alex Sapir's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alex Sapir has not made any transactions after 2024-03-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Alex Sapir
Alex Sapir Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Alex Sapir owns 3 companies in total, including PhaseBio Pharmaceuticals Inc (PHASQ) , Dova Pharmaceuticals Inc (DOVA) , and Fulcrum Therapeutics Inc (FULC) .
Click here to see the complete history of Alex Sapir’s form 4 insider trades.
Insider Ownership Summary of Alex Sapir
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PHASQ | PhaseBio Pharmaceuticals Inc | 2020-02-12 | director |
| DOVA | Dova Pharmaceuticals Inc | 2018-08-14 | director & President & CEO |
| FULC | Fulcrum Therapeutics Inc | 2024-03-04 | director & See Remarks |
Alex Sapir Latest Holdings Summary
Alex Sapir currently owns a total of 2 stocks. Among these stocks, Alex Sapir owns 68,609 shares of Dova Pharmaceuticals Inc (DOVA) as of August 14, 2018, with a value of $2 Million and a weighting of 93.11%. Alex Sapir also owns 43,360 shares of Fulcrum Therapeutics Inc (FULC) as of March 4, 2024, with a value of $142,438 and a weighting of 6.89%.
Latest Holdings of Alex Sapir
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DOVA | Dova Pharmaceuticals Inc | 2018-08-14 | 68,609 | 28.04 | 1,923,796 |
| FULC | Fulcrum Therapeutics Inc | 2024-03-04 | 43,360 | 3.29 | 142,438 |
Holding Weightings of Alex Sapir
Alex Sapir Form 4 Trading Tracker
According to the SEC Form 4 filings, Alex Sapir has made a total of 0 transactions in Dova Pharmaceuticals Inc (DOVA) over the past 5 years. The most-recent trade in Dova Pharmaceuticals Inc is the acquisition of 21,700 shares on August 14, 2018, which cost Alex Sapir around $495,411.
According to the SEC Form 4 filings, Alex Sapir has made a total of 1 transactions in Fulcrum Therapeutics Inc (FULC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Fulcrum Therapeutics Inc is the acquisition of 43,360 shares on March 4, 2024, which cost Alex Sapir around $492,136.
Insider Trading History of Alex Sapir
- 1
Alex Sapir Trading Performance
GuruFocus tracks the stock performance after each of Alex Sapir's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Alex Sapir is -16.27%. GuruFocus also compares Alex Sapir's trading performance to market benchmark return within the same time period. The performance of stocks bought by Alex Sapir within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Alex Sapir's insider trading performs compared to the benchmark.
Performance of Alex Sapir
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -8.74 | | | | | |
| Relative Return to S&P 500(%) | -10.21 | | | | | |
Alex Sapir Ownership Network
Ownership Network List of Alex Sapir
Ownership Network Relation of Alex Sapir
Alex Sapir Owned Company Details
What does PhaseBio Pharmaceuticals Inc do?
Who are the key executives at PhaseBio Pharmaceuticals Inc?
Alex Sapir is the director of PhaseBio Pharmaceuticals Inc. Other key executives at PhaseBio Pharmaceuticals Inc include 10 percent owner New Enterprise Associates 13 Lp , VP & Human Resources Glen Burkhardt , and Chief Commercial Officer Jonathan Birchall .
PhaseBio Pharmaceuticals Inc (PHASQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
PhaseBio Pharmaceuticals Inc (PHASQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
PhaseBio Pharmaceuticals Inc Insider Transactions
Alex Sapir Mailing Address
Above is the net worth, insider trading, and ownership report for Alex Sapir. You might contact Alex Sapir via mailing address: C/o Dova Pharmaceuticals, Inc., 240 Leigh Farm Road, Suite 245, Durham Nc 27707.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
